Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors [PDF]
Molecules, 2020 Aprepitant, a lipophilic and small molecular representative of neurokinin 1 receptor antagonists, is known for its anti-proliferative activity on numerous cancer cell lines that are sensitive to Substance P mitogen action.
Paweł K. Halik +5 more
doaj +6 more sources
Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer [PDF]
Journal of Clinical MedicineAlthough advances in pediatric oncology have resulted in cure rates exceeding 80% among children with cancer, progress in survival outcomes has begun to plateau in recent years. Mortality in this population remains largely associated with aggressive disease features, particularly tumor resistance to chemotherapy and metastatic spread. At the same time,
Marisa Rosso +2 more
exaly +4 more sources
Effectiveness of aprepitant in post‐acute COVID19 syndrome
Clinical Case Reports, 2021 This is the first case of a patient taking aprepitant for a post‐acute COVID‐19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.
Rocío Reinoso‐Arija +3 more
doaj +3 more sources
The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors
Current Oncology, 2021 Rhabdoid tumors (RT) are among the most aggressive tumors in early childhood. Overall survival remains poor, and treatment only effectively occurs at the cost of high toxicity and late adverse effects. It has been reported that the neurokinin-1 receptor/
Julian Kolorz +13 more
doaj +2 more sources
Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer [PDF]
Current OncologyBackground: Chemotherapy-induced nausea and vomiting (CINV) remains one of the significant challenges in oncology despite guideline-based prophylaxis, particularly in patients receiving highly emetogenic chemotherapy (HEC).
Akif Doğan +4 more
doaj +2 more sources
Innovative Tools and Perspectives in Cough Management: Cancer and Cough [PDF]
Tuberculosis and Respiratory DiseasesCough is a prevalent symptom in lung cancer that impairs quality of life. Postoperative cough after pulmonary resection (CAP) has an incidence of approximately 21.1%–55.8%.
Juwhan Choi, Sung Yong Lee
doaj +2 more sources
Anti‐Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin‐1 Pathway [PDF]
Cancer MedicineBackground Glioblastoma (GB) is an aggressive brain tumor characterized by rapid proliferation, invasion, and resistance to therapy. The substance P (SP)/neurokinin‐1 receptor (NK‐1R) pathway contributes to GB progression by promoting angiogenesis ...
Selin Engür‐Öztürk +2 more
doaj +2 more sources
Comparison of aprepitant, dexamethasone, and ondansetron with dexamethasone and ondansetron for prevention of postoperative nausea and vomiting in high-risk patients undergoing laparoscopic surgeries: a randomized controlled trial in India [PDF]
Journal of Minimally Invasive SurgeryPurpose: Following laparoscopic surgeries, patients often experience discomfort and dissatisfaction due to postoperative nausea and vomiting (PONV), despite using a multimodal pharmacological approach.
Shalini Bala +5 more
doaj +2 more sources
In Vitro Biological Evaluation of Aprepitant Based 177Lu-Radioconjugates
Pharmaceutics, 2022 Currently, the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed.
Paweł K. Halik +5 more
doaj +1 more source
Cancer Biology & Medicine, 2021 Objective: Chemotherapy-induced nausea and vomiting (CINV) are common with doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor ...
Winnie Yeo +12 more
doaj +1 more source